| Epidemiology from Literature | | Cohort | Year | Country | Test | Subjects | Positive (%) | Bibliography | | 1.1 - Asymptomatic | 2014 | Spain | IgE | 50 | 0.000 | 20140625, Armentia A
| | 1.10 - Any allergy symptom, Diagnosed | 2010 | Belgium | IgE | 86 | 2.325 | 20101214, Gadisseur R
| | 1.10 - Any allergy symptom, Diagnosed | 2013 | Germany | IgE | 8 | 0.000 | 20131202, Cifuentes L
| | 1.10 - Any allergy symptom, Diagnosed | 2011 | Spain | IgE | 1018 | 14.150 | 20111011, Vidal C
| | 1.11 - Esophagitis, Diagnosed | 2014 | Spain | IgE | 67 | 0.000 | 20140625, Armentia A
| | 1.11 - Esophagitis, Diagnosed | 2013 | Switzerland | IgE | 35 | 8.570 | 20130605, Simon D
| | 1.2.1 - Asthma, Diagnosed (Adults) | 2012 | Sweden | IgE | 96 | 0.000 | 20120528, Patelis A
| | 1.9 - Pollen Allergy | 2014 | Spain | IgE | 50 | 0.000 | 20140625, Armentia A
| | 10.1 - Normal Control | 2012 | Belgium | IgE | 27 | 0.000 | 20110223, De Knop KJ
| | 10.1 - Normal Control | 2009 | Belgium | IgE | 26 | 0.000 | 20091121, Ebo DG
| | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 2011 | China | IgE | 100 | 1.000 | 20111214, Zheng YW
| | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 2010 | Germany | IgE | 59 | 6.780 | 20100819, Hofmann SC
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2009 | Belgium | IgE | 22 | 4.550 | 20091121, Ebo DG
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2009 | Belgium | IgE | 20 | 5.000 | 20091121, Ebo DG
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Belgium | IgE | 37 | 10.810 | 20090826, Ebo DG
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2012 | Spain | IgE | 44 | 18.180 | 20120110, Monsalve RI
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2008 | Switzerland | IgE | 100 | 17.000 | 20081218, Muller UR
| | 5.1.1 - Source Exposed (Symptoms) | 2014 | France | IgE | 327 | 34.600 | 20140427, Lambert C
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 2010 | Germany | IgE | 34 | 79.410 | 20100819, Hofmann SC
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2012 | Belgium | IgE | 99 | 14.140 | 20110223, De Knop KJ
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Germany | IgE | 144 | 72.200 | 20140120, Kohler J
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2010 | Austria | IgE | 7 | 100.000 | 20100514, Mittermann I
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2010 | Germany | IgE | 20 | 70.000 | 20100326, Blank S
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2002 | Germany | IgE | 13 | 69.200 | 2002, Binder M
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2010 | Slovenia | IgE | 16 | 93.750 | 20100514, Mittermann I
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2008 | Switzerland | IgE | 99 | 96.960 | 20081218, Muller UR
| | 5.6.1 - Source Exposed (IgE) | 2011 | Slovenia | IgE | 184 | 91.840 | 20110412, Korosec P
| | 6.2 - General Population (Adults) | 2012 | Sweden | IgE | 371 | 0.270 | 20120528, Patelis A
| | 6.6 - Source Exposure | 2013 | Thailand | IgE | 50 | 12.000 | 20131016, Lao-Araya M
|
|
Loading...
Api m 1
